Guan Xing

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

Jeffrey A. Jones, Tadeusz Robak, Jennifer R. Brown et al. · The Lancet Haematology · 2017 · 198 citations

Medicine, Oncology, Pharmacology +10

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

Naval Daver, Paresh Vyas, Suman Kambhampati et al. · Journal of Clinical Oncology · 2023 · 121 citations · Full text

Medicine, Immunology, Pharmacology +17

Biomarker Analysis of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Ixabepilone or Paclitaxel in Early-Stage Breast Cancer

Christine E. Horak, Lajos Pusztai, Guan Xing et al. · Clinical Cancer Research · 2013 · 108 citations

Medicine, Oncology, Pharmacology +14

Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

Jacob D. Soumerai, Ai Ni, Mohamed Darif et al. · The Lancet Haematology · 2019 · 67 citations · Full text

Medicine, Immunology, Oncology +16

Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia

Pamela S. Becker, James M. Foran, Jessica K. Altman et al. · Blood · 2014 · 60 citations

Medicine, Hematology, Pharmacology +15